Quality Assurance Scheme Development Group
The Quality Assurance Scheme Development Group (QASDG) will develop the European Quality Assurance Scheme for Breast Cancer Services (the European QA scheme) to set common quality and safety requirements for person-centred breast cancer services in Europe. The scheme will cover all the processes of breast cancer care (screening, diagnosis, treatment, rehabilitation & supportive care, follow-up & survivorship care and palliative care) and will be underpinned by the accreditation legal framework and evidence from guidelines.
The QASDG discusses and selects the requirements within virtual working environments and in meetings organised every three months.
The members are also invited to contribute to the other ECIBC objectives, the Digital Mammography Training Template and the European Guidelines Platform covering all processes of care (from screening to end-of-life care).
The QASDG is supported by the external contractors EA- European Co-operation for Accreditation for the accreditation legal framework and for the coordination of national accreditation bodies, by CCIb –Iberoamerican Cochrane Centre for literature review and by IQ healthcare to develop indicators.
Members and external experts
Sabine Siesling was born in the Netherlands in 1972.
She studied Biomedical Science at the Leiden University and graduated in 1996, after she spend half an year at the University of Heidelberg, Germany. She finalised her PhD and was registered as clinical epidemiologist B.
Since 1999 she works at the Netherlands Comprehensive Cancer Organisation, Utrecht.
At this moment she is senior researcher and is project leader of the NABON Breast Cancer Audit, which is one of the key-indicators for the Dutch Health Care Inspectorate.
She is workpackage leader of the RARECAREnet project, aiming for centres of expertise for patients with rare cancers.
She is Professor at the MIRA Institute of Biomedical Technology and Technical Medicine, department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands.
Her chair focusses on outcomes research and personalised cancer care.
She is involved in several PhD projects in which the effect of interventions, like peer review or care pathways, on the quality of care is evaluated by using the data of the Netherlands Cancer Registry.
She is investigating clinical guideline adherence, personalised medicine and tailored follow-up.
Moreover, she is involved in the Netherlands Breast Cancer Project, which tries to fill the gaps in evidence for systemic treatment regimes, which cannot be obtained by RCT’s.She is general secretary of the International Association of Cancer Registries (IACR), president of the Netherlands Epidemiological Society, and board member of the FEDERA (Federation of Dutch Medical Scientific Societies).